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Abstract
Introduction: The use of screening mammography is still under debate within the medical community. The aim of
this study is to define a balance sheet of benefits (breast cancer mortality reduction) and harms (overdiagnosis) for
mammography screening programs.
Methods: We compared breast cancer incidence and mortality in two cohorts of women, defined as ‘attenders’ or
‘non-attenders’ on the basis of the individual attitudes towards screening, who were invited to the first round of
the Florentine screening program. The effects of screening exposure on breast cancer incidence and mortality
were evaluated by fitting Poisson regression models adjusted for age at entry, marital status and deprivation index.
We performed a sensitivity analysis excluding 34 women not responding to the invitation with a breast cancer
diagnosis in the following six months.
Results: In total, we included 51,096 women aged 50 to 69 years invited at the first screening round (1991 to
1993) and followed-up for breast cancer incidence and mortality until 31 December 2007 and 31 December 2008,
respectively The estimate of mortality reduction varies from 45% among 50 to 59 year-old women up to 51%
among 60 to 69 year-old women. The estimate of overdiagnosis, according to the cumulative-incidence method, is
an additional 10% of all breast cancer cases among 60 to 69 year-old women screened.
Conclusions: Comparing the breast cancer mortality and breast cancer incidence between attenders and non-
attenders, we have determined that the overall cost to save one life corresponds to no more than one over-
diagnosed tumor (from 0.6 to 1 depending on the selection criteria of the cohort), even if a residual self-selection
bias cannot be excluded.
Introduction
The efficacy of mammography screening programs has
been assessed in large randomized trials conducted in
the 1970s and 1980s both in Europe and in North
America [1-3]. Moreover, the effectiveness of popula-
tion-based screening in the context of routine health
care has been proven in many European countries using
different approaches (incidence-based mortality and
case-control approaches) [4-8].
Nevertheless, the use of screening mammography is
still under debate and the effectiveness of mammogra-
phy screening programs in reducing breast cancer
mortality was recently questioned on the basis of two
observational studies [9,10]. In addition, some authors
have highlighted potential negative side effects of mam-
mography screening. In particular they have raised the
problem of overdiagnosis [11,12], considered to be the
most important harm associated with early detection.
Although criticisms of mammography screening were
based on dubious methodology - that has been widely
criticized [13,14] - the estimation of the absolute bene-
fits and harms of mammography screening for breast
cancer remains a subject of discussion [15-17]. There-
fore an evaluation based on the experience of service
screening programs in Europe is urgent.
The best method to assess the impact of service
screening is the cohort approach, a study design includ-
ing subjects followed up in time both for their
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experience of screening and for the outcomes. In this
paper breast cancer incidence and mortality in the
group of women invited to the Florentine screening pro-
gram are presented. Two cohorts of women, identified
on the basis of the individual attitude towards screening,
are compared in order to obtain an estimate of the ratio
between benefits and harms of mammography screen-
ing, in terms of absolute numbers of lives saved and
absolute numbers of tumors overdiagnosed.
Materials and methods
The Florentine screening program began in 1991, offer-
ing high-quality mammography every 2 years to all resi-
dent women aged 50 to 69 years [18]. The attendance
rate was 56% at the prevalence round and it has
increased to about 70% in recent years. Performance
indicators including diagnosis and treatment are col-
lected annually under a national survey carried out by
the National Center for Screening Monitoring [19] on
behalf of the Italian Ministry of Health.
The cohort included the 52,282 women 50 to 69 years
old who were invited to the first screening round of the
Florentine screening program (1991 to 1993). The fact
of having had a previous diagnosis of breast cancer is a
reason for non-response to invitation. Therefore we
excluded 264 women with a prior breast cancer diagno-
sis as registered in the Tuscany cancer registry [20].
Moreover, we excluded 922 women who had migrated
outside the screening area before the second invitation
as registered in the municipality register.
The screening histories of all women in the cohort,
including the dates of invitations and the dates of all
their screening tests following the invitations, if any,
were extracted from the local computerized screening
database. Screening exposure was defined on the basis
of attendance at the first two rounds and the women
were classified as:
1) frequent attenders, if they responded to both
invitations,
2) irregular attenders, if they responded to only one
invitation,
3) never attenders, if they not responded to any of the
first two invitations.
For the women invited only to the first round (n =
5,757) since they were not eligible for the second round
(due to cancer diagnosis, age limit, recent spontaneous
screening mammography, and so on) screening exposure
was defined as frequent or never attenders on the basis
of the attendance at the first round.
In order to verify the correlation between attendance
at the first two rounds and at successive rounds, the
whole screening history of the women up to 31 Decem-
ber 2008 was collected. A total of 84% of women who
were classified as ‘never’ did not attend any test in the
study period. For the women classified as ‘frequent’ and
‘irregular’ the average attendance at the successive
rounds, calculated as the total number of performed
tests compared to the total number of invitations
received from the third round onwards, is 90% and 67%,
respectively. Because of the similar screening attendance
frequent and irregular attenders were combined together
in the ‘attenders’ category (that is, all women who
responded to at least one invitation in the first two
rounds), in order to obtain more reliable estimates for
the balance sheet.
All women were followed-up for breast cancer inci-
dence until 31 December 2007 through a linkage with
the Tuscan cancer registry [20] and pathology reports.
All women were followed-up for vital status and cause
of death until 31 December 2008 through a linkage with
the regional mortality registry and with the list of resi-
dents [21]. Person-years at risk were counted from the
date of first invitation to the date of event (breast cancer
diagnosis/breast cancer death) or to the date of censor-
ing (death due to other causes, emigration from Tuscany
or end of follow-up). Standardized incidence and mor-
tality rates were calculated using the European standard
population.
In order to verify the comparability of attenders and
non-attenders, information was collected on marital sta-
tus (at December 1995) and deprivation index (national
census 1991 data) for all women in the cohort. The
deprivation index was constructed at the national level
to measure relative socio-economic disadvantage [22]
and it is available at the level of census section (about
70 women for each section). Three socio-economic
classes were defined using tertiles of the index distribu-
tion in the Florentine area.
Furthermore, in order to enhance the comparability of
these two groups, we performed a sensitivity analysis
excluding 34 women not responding to the invitation
who had a breast cancer diagnosis in the following six
months. The underlying assumption is that these
women were already undergoing diagnostic assessment
when they received the invitation to screening.
The local ethics committee has authorized this study
as an observational retrospective study, aimed at public
health outcome research; therefore no consent by sub-
jects was needed according to the national law.
Statistical Analysis
In order to evaluate benefits and harms of mammogra-
phy screening programs, breast cancer mortality reduc-
tion and overdiagnosis was taken into consideration.
The effects of screening exposure on breast cancer mor-
tality and breast cancer incidence were evaluated by fit-
ting Poisson regression models adjusted for age at entry
(five-years class), marital status and deprivation index.
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Due to the length of our incidence follow-up (15.4
years median value), the breast cancer incidence rate
ratio can be considered a valid estimate of overdiagnosis
only for women 60 to 69 years old at entry, according to
the cumulative-incidence method [23]. In the cumula-
tive-incidence method a comparison is made of the
cumulative incidence among a group of women who
were screened with the cumulative incidence in a non-
screened group over the same time period. The compari-
son should be carried out several years (at least five) after
screening ends, in order to take into account the lead
time attributable to screening [23]. Indeed, in a previous
paper [24] we showed that 90% of incremental cases are
expected to be decremental five years after screening
stops. The younger cohort, 50 to 59 years old at the
entry, will be 65 to 74 years old at the end of the study
period. Therefore they were still being invited to screen-
ing or the follow-up period after the last screening was
not long enough. The older cohort, 60 to 69 years old at
the entry, will be 75 to 84 years old at the end of the
study period, that is, they were followed for 5 to 14 years
after the end of screening. Therefore, the follow-up per-
iod was long enough to take into account the lead time
and to provide a correct estimate of overdiagnosis.
The balance sheet was constructed by estimating the
number of lives saved and the number of overdiagnosed
cases among 1,000 60 to 69 year-old women screened
until the screening age limit (69 years) and followed for
15 years. The absolute number of lives saved was calcu-
lated in a two-step process:
1) the risk of breast cancer death in the absence of
screening was estimated from the breast cancer mortal-
ity rates observed in the cohort of non-attenders.
2) the number of lives saved was calculated by apply-
ing our mortality reduction estimate to the number of
breast cancer deaths expected in the absence of
screening.
The absolute number of overdiagnosed cases was cal-
culated using a similar procedure.
Results
In total, we studied 51,096 women who were 50 to 69
years old at the first invitation of the Florentine screen-
ing program. Overall 64% of the women (n = 32,544)
responded to at least one invitation in the first two
rounds. This is the group of ‘attenders’ composed of
48% frequent attenders and 16% irregular attenders. The
‘non-attenders’ did not responded to any of the first two
invitations and constituted 36% of the total (n = 18,552).
Over the study period, attenders aged 50 to 59 and 60
to 69 years at the first invitation had 6.0 and 3.3 screen-
ing mammograms on average, respectively.
As shown in Table 1 attenders were significantly
younger than non-attenders (mean age was 59.1 and
60.9 years, respectively, P < 0.0001). The distribution of
marital status was very different by screening exposure:
70% of attenders were married compared to only 57% of
non-attenders (P < 0.0001). Furthermore, attenders and
non-attenders differed by socio-economic status: the
percentage of women who lived in a deprived area (that
is, a census section classified in the third tertile of the
deprivation index distribution) was 31.7% and 36.0% for
attenders and non-attenders, respectively (P < 0.0001).
Overall, 1,583 (4.9%) breast cancers were diagnosed dur-
ing the follow-up period among the attenders and 782
(4.2%) among non-attenders. The number of breast can-
cer deaths observed in the cohort was 184 (0.6%) and
218 (1.2%) for attenders and non-attenders, respectively.
All women were followed up for vital status with a
median follow-up time of 16.5 years. In total, we
observed 9,641 deaths from all causes of which 402
were deaths from breast cancer. Standardized mortality
rates from breast cancers were 3.6 and 7.5 per 10,000
for screened and never attenders, respectively. In Figure
1 we show the standardized mortality rates from breast
cancer (per 10,000) by time from first invitation. Mortal-
ity rates of attenders and non-attenders were similar in
the first three to four years after invitation and diverged
progressively over time.
All women were followed up for incidence with a
median follow-up of 15.4 years. In total, we observed
2,365 incidence breast cancers (2,186 invasive and 179
in situ). Standardized breast cancer incidence rates (per
1,000) were 3.4 and 3.0 for attenders and non-attenders,
respectively.
In Figure 2 we report the standardized breast cancer
incidence rates (per 1,000) by time from first invitation
for women 60 to 69 years old at entry. During the first
years we observed the incidence peak in the attenders
Table 1 Women characteristics by screening exposure
Attenders Non-attenders
N° of women 32,544 18,552





Widow 19.7% 24.5% p < 0.0001
Deprivation index (%)
First tertile 34.0% 31.3%
Second tertile 34.3% 32.7%
Third tertile 31.7% 36.0% p < 0.0001
N° (%) of breast cancer 1,583 (4.9%) 782 (4.2%)
In situ 143 (0.4%) 36 (0.2%)
Invasive 1,440 (4.4%) 746 (4.0%)
N° (%) of BC deaths 184 (0.6%) 218 (1.2%)
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Figure 1 Standardized mortality rates from breast cancer (per 10,000) by time from first invitation (three-years moving averages).



























Figure 2 Standardized breast cancer incidence rates (per 1,000) by time from first invitation (three-year moving averages). Women 60
to 69 years old at entry.
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due to the prevalence round. The differences between
the two groups were gradually reabsorbed as the women
were no longer actively invited.
In Table 2 the number of cases, person-years and rate
for breast cancer mortality and incidence are shown by
age at entry and exposure to screening. The rate ratio
was adjusted for age, marital status and deprivation
index. The estimate of mortality reduction varies from
45% among 50 to 59 year olds up to 51% among 60 to
69 year olds. The estimate of overdiagnosis, according
to the cumulative-incidence method, is an additional
10% of breast cancer cases (invasive and in situ) among
those screened. The estimate of overdiagnosis for inva-
sive breast cancer only was 5% (1.05; 95%CI: 0.93 to
1.18).
Using the rates for non-attenders, the 15-year risk of
breast cancer (in situ and invasive) for women 60 to 69
years old was 5.7% and the risk of dying from breast
cancer in the same age class was 1.8%. Therefore,
screening 1,000 women 60 to 69 years old until the
screening age limit (performing an average of three
screening mammograms each) may prevent about 9
breast cancer deaths out of 18 expected and could lead
to an overdiagnosis of about 6 cases out of 57 expected,
including carcinoma in situ, leading to a balance of 0.6
tumors overdiagnosed for every life saved.
Sensitivity analysis
We performed a sensitivity analysis excluding 34 women
not responding to the invitation with a breast cancer
diagnosis in the following 6 months. The estimate of
mortality reduction remains essentially unchanged (43%
and 48% for the 50 to 59 and 60 to 69 year olds) but
the estimate of overdiagnosis increases to 15% for all
breast cancers (10% for invasive only), so leading to a
balance of one tumor overdiagnosed for every life saved.
Discussion
Although mammography screening is one of the screen-
ing programs most carefully studied, it continues to be
one of the most debated issues within the medical com-
munity [25]. The effectiveness of mammography screen-
ing programs in reducing breast cancer mortality was
recently questioned [9,10]. Moreover, the problem of
overdiagnosis with mammography screening has been
raised by several authors who have tried to quantify
overdiagnosis of breast cancer [23]. The estimates
obtained vary widely, depending on the method used,
leading to a much heated debate between supporters of
opposite positions [15,16].
The main challenge in quantifying the reduction in
mortality and the overdiagnosis from screening pro-
grams is to provide valid comparison groups. In service
screening, in fact, a control group is not available since
the entire target population is invited to be screened. In
most studies the method used to overcome this problem
is to estimate the incidence or mortality expected in the
absence of screening, modelling the incidence or mortal-
ity rates observed before the start of the screening pro-
gram [24,26-29]. However, the estimate of expected
rates is subject to a strong statistical uncertainty and it
strongly influences the estimate of the final outcome
(mortality reduction or overdiagnosis).
In the present study, a comparison was made between
two observed cohorts, the cohort of women who
responded to at least one invitation in the first two
rounds (attenders) and the cohort of women who did
not respond to any invitation in the first two rounds
(non-attenders), thus overcoming the problem of esti-
mating the expected. On the other hand, due to the
well-known self-selection bias (women who accept the
invitation to screening may have a baseline risk for
breast cancer incidence and mortality different from
Table 2 Number of cases, person-years, rates and rate ratios for breast cancer mortality and incidence by age at entry
among attenders and non-attenders
Breast cancer mortality
Age at entry Exposure BC deaths Person years BC mortality rate
(per 10,000)
Adjusted rate ratio (*)
50-59 Non-attenders 77 113 409 6.8 1
Attenders 90 270 399 3.3 0.55 (0.41 - 0.75)
60-69 Non-attenders 141 151 615 9.3 1
Attenders 94 233 543 4.0 0.49 (0.38 - 0.64)
Breast cancer incidence
Age at entry Exposure BC cases (**) Person years BC incidence rate (per 1,000) Adjusted rate ratio (*)
50-59 Non-attenders 321 105 635 3.0 1
Attenders 838 249 896 3.4 1.15 (1.01 - 1.31)
60-69 Non-attenders 461 142 547 3.2 1
Attenders 745 216 309 3.4 1.10 (0.98 - 1.23)
(*) Adjusted for age, marital staus and deprivation index. (**) Include in situ and invasive BC cases
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that of women who do not accept the invitation to
screening) the comparison between attenders and non-
attenders can be biased. A correction for self-selection
bias was made using the information about marital sta-
tus and socio-economic status of the women [30].
Furthermore, in order to enhance the comparability of
these two groups, we performed a sensitivity analysis
excluding 34 women who had not responded to the
invitation and who had a breast cancer diagnosis in the
following 6 months (the underlying assumption is that
these women were already undergoing diagnostic assess-
ment when they received the invitation to screening).
Nevertheless we cannot exclude the presence of a resi-
dual self-selection bias.
It should be noted that the issue of comparability
between attenders and non-attenders is the main limita-
tion of this study and it can influence either mortality
or incidence results. As far as mortality is concerned,
several studies suggested that non-attenders have a
higher baseline risk of breast cancer mortality compared
to a control group [31] even if other authors found the
opposite [32]. As far as we know, there is no consistent
evidence in the literature about different underlying
incidence risks in attenders compared with non-atten-
ders. In our dataset, attenders belong to a higher socio-
economic class and are more frequently married than
never attenders. The first factor is probably associated
with higher underlying incidence while the second one
with lower underlying incidence, resulting in an
unknown net effect. Therefore, it is not clear in which
direction the self-selection bias could have influenced
our results.
Screening exposure was defined on the basis of atten-
dance at the first two rounds. A tendency to maintain
the same behavior over time (called ‘attitude towards
screening’) was noted in the Italian annual screening
survey [33] and also in other countries [34]. The above
data support this assumption, too. Indeed 84% of
women who did not respond to the first two rounds still
did not respond to the successive rounds and 91% of
women who responded to at least one invitation in the
first two rounds also responded to at least one more
invitation in successive rounds. Nevertheless, a misclas-
sification of exposure may occur in a small number of
women. The misclassification of exposure between
attenders and non-attenders could lead to a bias towards
the null hypothesis, which means a possible underesti-
mation of both mortality reduction and overdiagnosis.
The aim of this paper is to define a balance sheet of
benefits (breast cancer mortality reduction) and harms
(overdiagnosis) for service mammography screening. It
has been estimated that, if 1,000 women 60 to 69 years
old at entry were screened until the age limit (perform-
ing an average of three screening mammograms each)
about 9 women will benefit from the screening, because
they will avoid dying from breast cancer, while about 6
women will be overdiagnosed and treated needlessly
(the expected figures in the absence of screening are 18
breast cancer deaths and 57 in situ and invasive breast
cancer cases). Therefore, the human cost to save one
life corresponds to 0.6 overdiagnosed tumours.
Our final balance sheet (between 0.6 and 1 tumor
overdiagnosed for every life saved) is consistent with the
results reported by Duffy on the basis of both experi-
mental and observational data from the Swedish Two-
County trial and from the Breast Screening Program in
England [16]. However, estimates from other authors,
Welch [24] and Gotzsche [12], give a much higher num-
ber of overdiagnosed tumors. It could be said that the
first step to comparing estimates from different studies
and to formulating a common balance sheet is to share
a common methodology. The estimate of overdiagnosis
is strongly dependent on the method used for the lead
time adjustment. The cohort approach with a long fol-
low-up after screening ends, as in this paper, is the best
approach to take into account the bias due to lead time
without using any statistical adjustment. Moreover, as
far as we know, this is the first observational cohort
study of invited women comparing both breast cancer
incidence and mortality between those who participated
and those who did not participate in screening (in other
words assessing both overdiagnosis and mortality reduc-
tion from the same cohort of women).
The balance sheet should be based on reliable esti-
mates both of mortality and on overdiagnosis. This
implies that agreement is reached on the best method
to obtain these estimates, on updating these estimates
continuously and in reaching context-specific estimates.
Our estimate of overdiagnosis resulted in an additional
10% of in situ and invasive breast cancer cases and it
was reduced to 5% when invasive cancers only were
considered. These data show that a large part of over-
diagnosis is due to carcinoma in situ even if we cannot
draw conclusions about whether and how the detection
of carcinoma in situ could lead to an incidence reduc-
tion in invasive cases. Therefore, the actual estimate of
overdiagnosis to be used in the balance sheet should
include carcinoma in situ.
Furthermore, in order to reduce the burden of over-
diagnosis, it is essential to understand better the natural
history of small lesions. Indeed, it should be recalled
that the information available in order to predict tumor
progression and aggressiveness is very poor, especially
for carcinoma in situ. Further research is needed to
improve understanding of the markers of tumor pro-
gression and so to reduce the burden of treatment in
early breast cancer cases which is the most important
and needed consequence of screening.
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Conclusions
The best method to assess the impact of service screen-
ing is the cohort approach, a study design including
subjects followed up in time both for their experience of
screening and for the outcomes. As far as we known,
this is the first observational cohort study of invited
women comparing both breast cancer incidence and
mortality between those who participated and those
who did not participate in screening. Comparing breast
cancer mortality and breast cancer incidence between
attenders and non-attenders, we have estimated that the
overall cost to save one life corresponds to no more
than one overdiagnosed tumor (from 0.6 to 1 depending
on the selection criteria of the cohort), even if a residual
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